Donald Trump and his wife Melania at an election night watch event in West Palm Beach, FL (Lynne Sladky/AP Images)

November 6, 2024 07:22 AM ESTUpdated 07:39 AM

New Trump era could be a boon for biopharma M&A, dealmaking

Zachary Brennan

Senior Editor

As former President Donald Trump returns to power — the Associated Press projected his presidential victory Wednesday morning — the biopharma industry may see the door open …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New Trump era could be a boon for biopharma M&A, dealmaking

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

Acadia lands $150M sale of rare pediatric PRV

Novo unveils new cardiometabolic data as it reports solid third-quarter profits

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

New Trump era could be a boon for biopharma M&A, dealmaking